DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Wegovy mimics GLP‑1, a natural gut hormone. It slows gastric emptying, reduces appetite, and signals fullness — leading to reduced caloric intake.
Wegovy (semaglutide 2.4mg) is a glucagon-like peptide-1 receptor agonist. It mimics GLP-1, a natural gut hormone released after eating. Three mechanisms drive weight loss: (1) Slows gastric emptying — food stays in your stomach longer, prolonging fullness; (2) Acts on appetite-regulation centers in the hypothalamus — reduces hunger signals and "food noise" (intrusive thoughts about food); (3) Improves insulin sensitivity and glucagon regulation. Net effect: in a 20-week trial, people on semaglutide 2.4 mg ate 35% less at an all-you-can-eat lunch than those on placebo. One year after stopping, STEP 1 participants regained two-thirds of their prior weight loss. The cardiovascular outcomes from SELECT trial suggest benefits beyond weight loss, particularly in patients with established CVD.
Editorial answer verified against FDA labeling and peer-reviewed trials, with sources cited. Not medical advice. Coordinate treatment decisions with your prescriber.